BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights…
NEW ROCHELLE, N.Y., Feb. 27, 2025 /PRNewswire/ -- A new article in Autism and Adulthood presents guidelines for designing consent materials…
– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase…
--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint…
Ottawa, Ontario--(Newsfile Corp. - February 12, 2025) - More than half of Canadians lack a comprehensive retirement plan, and of…
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses…
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim…
– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly…
– New blinded preliminary BRTX-100 data described this past Saturday at prestigious “2025 Winners in Industry Innovations in MSK Health”…
ROSEMONT, Ill., Feb. 7, 2025 /PRNewswire/ -- Nicolas S. Piuzzi, MD, was recognized as the 2025 Kappa Delta Young Investigator Award…